Author: Vigilare Biopharma

  • Home
  • Vigilare Biopharma

Navigating the Complexities of Global Regulatory Submissions

Each country has unique regulations and documentation requirements, making it essential to develop a comprehensive strategy to ensure compliance across various regions. Here are some key strategies and tools to streamline the global regulatory submissions

Read More
How Vigilare Biopharma Helps You Get Your Medical Devices Approved by the FDA

Get Your Medical Devices Approved by the FDA

How Vigilare Biopharma Helps You Get Your Medical Devices Approved by the FDA Navigating the complex landscape of FDA approval for medical devices can be daunting. At Vigilare Biopharma, we specialize in guiding companies through

Read More

Hyderabad Global Capability Centre’s as Pharma Hub

Hyderabad, the capital of Telangana, has emerged as a prominent pharma hub in India, attracting global pharmaceutical companies and investors. Its strategic location, coupled with a favourable business environment, has made it a preferred destination

Read More

Important Regulatory Changes in USFDA for Pharma Companies in 2024 to File an NDA

The USFDA’s 2024 regulatory changes At Vigilare Biopharma, we understand the complexities and challenges that pharmaceutical companies face when navigating the ever-evolving regulatory landscape. The USFDA’s 2024 regulatory changes reflect a significant shift towards enhancing

Read More

Outsourcing Pharmacovigilance to CROs: Benefits, Challenges and Best Practices

How CROs Can Support Pharmacovigilance and Regulatory Compliance? Pharmacovigilance is the process of monitoring, evaluating, and preventing adverse reactions or any other problems related to medicines. It is an essential part of drug development and

Read More

How decentralized clinical trials-DCTs are transforming clinical research and patient care?

DCTs are not a fad, but a trend that is transforming clinical research and patient care. By leveraging technology to make trials more accessible

Read More
FDA Approves First Oral Treatment for Postpartum Depression

FDA Approves Zurzuvae: First Oral Medication for Postpartum Depression (PPD)

The U.S. Food and Drug Administration (FDA) has given its stamp of approval to Zurzuvae (zuranolone), marking it as the first oral medication specifically designed to treat postpartum depression (PPD) in adults. PPD is a

Read More

Patient Engagement in Pharmacovigilance: Empowering Patients for Safer Healthcare

involving patients directly in pharmacovigilance efforts can be a game-changer. Patient engagement offers unique insights, enhances reporting systems, and fosters a collaborative approach to drug safety.

Read More

Pharmacovigilance in Medical Trends: Enhancing Drug Safety in the Evolving Healthcare Landscape

As healthcare advances, new treatment modalities, personalized medicines, and innovative technologies are reshaping the landscape.

Read More
Regulatory News

Regulatory and Pharma News July 21

Welcome to the latest edition of our Pharma News and Regulatory News Updates, where we bring you the most significant developments and breakthroughs in the pharmaceutical industry and the latest updates from regulatory agencies worldwide.

Read More
Quick Enquiry
close slider